Lilly reports second-quarter 2012 results

Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2012: Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partial…

---

Chimerix, Inc. Signs Worldwide License Agreement With Merck & Co., Inc. for Up to $168.5 Million

RESEARCH TRIANGLE PARK, N.C., July 24, 2012 /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclu…

---

MDxHealth Signs Worldwide Development & Commercialization Agreement With Merck KGaA for MGMT Diagnostic Test

Regulatory News MDxHealth SA NYSE Euronext MDXH a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment announced…

---